Markets:

Overview

News

Currencies

International

Treasuries

Biogen Idec (NQ:BIIB)

189.00 -1.56 (-0.82%)

Streaming Delayed Price Updated: 3:01 PM EDT, May 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

59 60 Next >

These S&P500 stocks have an unusual volume in today's session ↗

February 12, 2025

Let's take a closer look at the S&P500 stocks with an unusual volume in today's session on Wednesday. Stay informed about the market activity below.

Via Chartmill

These S&P500 stocks are moving in today's session ↗

February 12, 2025

Get insights into the S&P500 index performance on Wednesday. Explore the top gainers and losers within the S&P500 index in today's session.

Via Chartmill

Biogen (BIIB) Q4 2024 Earnings Call Transcript ↗

February 12, 2025

BIIB earnings call for the period ending December 31, 2024.

Via The Motley Fool

Topics Earnings

Stocks Trim Losses After Hot Inflation, Bonds Remain Pressured, Tesla Rebounds: What's Driving Markets Wednesday? ↗

February 12, 2025

A hotter-than-expected inflation report initially rattled markets on Wednesday morning, but investors found confidence to buy the dip, helping major indexes recover most losses by midday trading in New...

Via Benzinga

Topics Economy

Earnings Scheduled For February 12, 2025 ↗

February 12, 2025

Via Benzinga

Breaking Down Biogen: 18 Analysts Share Their Views ↗

January 28, 2025

Via Benzinga

Wednesday's session: gap up and gap down stock in the S&P500 index ↗

February 12, 2025

Let's have a look at what is happening on the US markets on Wednesday. Below you can find the S&P500 gap up and gap down stocks in today's session.

Via Chartmill

Biogen Stock Slides To Fresh 12-Year Lows As Profit Outlook Misses, But Retail Snaps Up The Dip ↗

February 12, 2025

The company's breakthrough Alzheimer's drug, Leqembi, generated $87 million in Q4 sales, well ahead of the $67 million analysts expected.

Via Stocktwits

Biogen Q4 Earnings: Revenue And EPS Beat, Warns Lower 2025 Revenue, Inks R&D Funding Pact With Royalty Pharma ↗

February 12, 2025

Biogen posted strong Q4 results, surpassing estimates, while forecasting a 2025 revenue decline. The company secured up to $250 million in R&D funding from Royalty Pharma.

Via Benzinga

Biogen’s (NASDAQ:BIIB) Q4 Sales Top Estimates

February 12, 2025

Biotech company Biogen (NASDAQ:BIIB) reported revenue ahead of Wall Street’s expectations in Q4 CY2024, with sales up 2.9% year on year to $2.45 billion. Its non-GAAP profit of $3.44 per share was 2.3%...

Via StockStory

Topics Artificial Intelligence

Why Investors Might Hammer Biogen Despite Its Earnings Beat ↗

February 12, 2025

Biogen beat Q4 views Wednesday, but guided lower on 2025 profit.

Via Investor's Business Daily

US Stocks Set For A Cautious Start Ahead Of Inflation Data: Expert Says 'Strong Bull Markets Tend To Roar Back To Life After Corrections' ↗

February 12, 2025

U.S. stock futures fell on Wednesday after a mixed close on Tuesday as Federal Reserve Chairman Jerome Powell Congress testimony.

Via Benzinga

Topics Economy

Biogen Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts ↗

February 12, 2025

Via Benzinga

What To Expect From Alzheimer's Drugmaker Biogen's Q4 Earnings On Wednesday? ↗

February 11, 2025

Biogen faces revenue challenges as Leqembi sales lag projections. Investors watch its pipeline expansion and strategic moves amid upcoming Q4 earnings.

Via Benzinga

Biogen (BIIB) Reports Earnings Tomorrow: What To Expect

February 11, 2025

Biotech company Biogen (NASDAQ:BIIB) will be announcing earnings results tomorrow morning. Here’s what to look for.

Via StockStory

Deal Dispatch: Sage And Silvus Are Up For Sale, MrBeast Secures $20B For TikTok ↗

January 31, 2025

Sage Therapeutics rejects Biogen deal offer; Silvus Technologies considers sale/IPO; Allakos downsizes; MrBeast bids on TikTok.

Via Benzinga

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union

January 31, 2025

From Biogen Inc.

Via GlobeNewswire

Biogen Rises On FDA Nod for Alzheimer's Drug Dosing Regimen, But Sage Deal Fallout Irks Retail ↗

January 27, 2025

The small-cap biotech firm called the proposal "significantly undervaluing" the company and added that it was not in the best interest of its shareholders.

Via Stocktwits

10 Worst Performing Large-Caps Last 12 Months ↗

January 27, 2025

Here’s this week’s top 10 worst performing Large-Caps in the last twelve months.

Via Talk Markets

Topics Stocks / Equities

FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

January 26, 2025

From Biogen Inc.

Via GlobeNewswire

FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA

January 23, 2025

Applications are based on data from the DEVOTE study, which demonstrate the potential for the investigational higher dose regimen of nusinersen to advance the treatment of SMA

From Biogen Inc.

Via GlobeNewswire

Deal Dispatch: Biden Punts TikTok Ban To Trump, Plus Another Legacy Retailer Goes Bankrupt ↗

January 17, 2025

Deal opportunities abound: KKR & Co.'s stake in Maya; DuPont's electronics business; Ingevity's North Charleston site; and S&W Seed Company.

Via Benzinga

Topics Government

10 Health Care Stocks With Whale Alerts In Today's Session ↗

January 14, 2025

Via Benzinga

FDA To Review Under the Skin Weekly Autoinjector For Biogen/Eisai's Alzheimer's Drug Leqembi ↗

January 14, 2025

FDA reviews Eisai and Biogen's BLA for Leqembi SC-AI, targeting Alzheimer's treatment with home-based weekly autoinjector dosing.

Via Benzinga

FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

January 13, 2025

LEQEMBI is the only FDA-approved anti-amyloid therapy that potentially could offer the convenience of a subcutaneous injection with at-home administration option

From Biogen Inc.

Via GlobeNewswire

Sage Therapeutics Stock Eyes Best Day In 5 Years On Biogen’s Unsolicited Bid: Retail Piles In ↗

January 13, 2025

The two companies have collaborated since 2020 on the depression drug Zurzuvae, approved in 2023 by the FDA for treating postpartum depression.

Via Stocktwits

Biogen Bid For Sage Therapeutics Could Strengthen Neurology Strategy: Analysts ↗

January 13, 2025

Biogen proposes acquiring Sage Therapeutics for $7.22 per share, as analysts highlight the strategic value of Zurzuvae's success in postpartum depression.

Via Benzinga

Crude Oil Surges 3%; Abercrombie & Fitch Shares Plunge ↗

January 13, 2025

Via Benzinga

Intra-Cellular Therapies, Standard BioTools, SI-BONE And Other Big Stocks Moving Higher On Monday ↗

January 13, 2025

Via Benzinga

Why Is Depression-Focused Sage Therapeutics Stock Surging Higher On Monday? ↗

January 13, 2025

Sage Therapeutics reviews Biogen's $7.22 per share acquisition proposal amid ongoing restructuring and focus on Zurzuvae for postpartum depression.

Via Benzinga

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

59 60 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.